Table 1.
BP mm Hg |
GRF | RPF | FF | RVR mm Hg/(ml/min) |
SNGFR | QA | PGC | PT | RA | RE | Kf nl/sec/mm Hg |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
ml/min | nl/min | mm Hg | 1010dyn × sec × cm−5 | |||||||||
Group I (NM A; N = 6) | ||||||||||||
Control | 99±1 | 1.35±0.04 | 3.5±0.1 | 0.39±0.02 | 15±1 | 57±1 | 231±18 | 57±1 | 13±1 | 0.85±0.08 | 0.95±0.08 | 0.042±0.003 |
+NMA | 131±2 | 1.16±0.06 | 2.3±0.1 | 0.50±0.02 | 29±2 | 44±2 | 120±14 | 79±3 | 14±2 | 1.96±0.30 | 2.87±0.26 | 0.019±0.001 |
P value | <0.001 | <0.01 | <0.005 | <0.005 | <0.001 | <0.005 | <0.001 | <0.001 | NS | <0.005 | <0.001 | <0.001 |
Group II (BOS + NMA; N = 7) | ||||||||||||
Control | 101±1 | 1.82±0.06 | 5.1±0.4 | 0.37±0.03 | 11±1 | 67±6 | 220±21 | 62±1 | 14±1 | 0.82±0.08 | 1.17±0.10 | 0.044±0.003 |
+BOS + NMA | 123±3a | 1.72±0.08 | 3.5±0.2 | 0.49±0.02 | 19±1a | 70±10a | 197±30a | 70±2a | 14±1 | 1.31±0.17a | 1.67±0.21a | 0.037±0.005a |
P value | <0.001 | NS | <0.05 | <0.05 | <0.001 | NS | NS | <0.005 | NS | <0.01 | <0.01 | <0.05 |
Group III (LOS + NMA; N = 8) | ||||||||||||
Control | 100±1 | 1.52±0.08 | 4.5±0.5 | 0.36±0.02 | 13±1 | 54±3 | 176±15 | 59±2 | 14±1 | 1.06±0.10 | 1.36±0.13 | 0.043±0.003 |
+LOS +NMA | 125±3a | 1.59±0.16 | 3.3±0.4 | 0.50±0.02 | 22±3 | 56±4a | 153±26a | 73±2a | 14±1 | 1.58±0.20a | 2.23±0.30a | 0.033±0.003a |
P value | <0.001 | NS | <0.05 | <0.001 | <0.005 | NS | NS | <0.001 | NS | <0.05 | <0.05 | <0.05 |
Group IV (LOS + BOS + NMA; N = 5) | ||||||||||||
Control | 108±3 | 1.17±0.07 | 4.1±0.4 | 0.30±0.02 | 15±2 | 39±2 | 119±11 | 65±2 | 12±1 | 1.66±0.26 | 2.27±0.32 | 0.026±0.002 |
LOS+BOS + NMA | 111±6 | 1.09±0.10 | 4.1±0.4 | 0.27±0.02 | 15±2 | 40±2 | 113±11 | 60±3 | 11±1 | 2.11±0.31 | 2.37±0.32 | 0.030±0.002 |
P value | NS | NS | NS | NS | NS | NS | <0.05 | NS | NS | <0.05 | NS | NS |
Values are mean ± se. Group I (NMA), acute systemic nitric oxide inhibition with N-monomethyl l-arginine (NMA) alone; Group II (BOS+NMA), combination of both ET blockade with a non-peptide ETA and ETB receptor antagonist bosentan (BOS) and NMA; Group III (LOS + NMA), combination of both angiotensin II inhibition with a selective AT1 receptor blocker losartan (LOS) and NMA; Group IV (LOS+BOS+NMA) combined angiotensin II AT1 and endothelin ETA and ETB receptor antagonism during acute systemic NOS inhibition with NMA. Abbreviations are: BP, mean blood pressure; GFR, glomerular filtration rate; RPF, renal plasma flow; FF, filtration fraction; RVR, renal vascular resistance; SNGFR, single nephron GFR; QA, glomerular plasma flow. PGC, glomerular blood pressure; PT, proximal tubule pressure; RA, preglomerular arteriolar resistance; RE, efferent arteriolar resistance; Kf, glomerular capillary ultrafiltration coefficient; NS, not significant. P values show significant difference by paired t-test.
Significant difference between the change from control to experimental for BOS + NMA (Group II) or LOS + NMA (Group III) versus NMA alone (Group I)